Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination.
about
Dendritic cell vaccines for brain tumorsAn update on vaccine therapy and other immunotherapeutic approaches for glioblastomaClinical efficacy of tumor antigen-pulsed DC treatment for high-grade glioma patients: evidence from a meta-analysisRationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy.Autophagy induced by conventional chemotherapy mediates tumor cell sensitivity to immunotherapy.Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice.Combining cytotoxic and immune-mediated gene therapy to treat brain tumorsA phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients.Immunotherapy in head and neck cancer: aiming at EXTREME precision.Gene therapy for brain cancer: combination therapies provide enhanced efficacy and safety.Trends in cancer immunotherapyAn unusual case of metastatic melanoma sensitive to chemotherapy and immunotherapy, with late immune escape in the brain.Overview of cellular immunotherapy for patients with glioblastoma.Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial.Cellular and vaccine therapeutic approaches for gliomasα-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial.Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme.Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy.INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect.Combined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen.Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: implications for clinical trial design.Cellular immunotherapy as maintenance therapy prolongs the survival of the patients with small cell lung cancer.Genetic analysis of intracranial tumors in a murine model of glioma demonstrate a shift in gene expression in response to host immunity.Cellular-based immunotherapies for patients with glioblastoma multiforme.Recent developments on immunotherapy for brain cancer.Dendritic cell-based immunotherapy for malignant gliomas.Immunotherapy for human glioma: innovative approaches and recent results.Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-κB signaling improves the efficacy of immunotherapy in a brain cancer modelClinical trials of gene therapy, virotherapy, and immunotherapy for malignant gliomas.Sensitization of malignant glioma to chemotherapy through dendritic cell vaccination.Dendritic cell immunotherapy for breast cancer.Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancerA phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05).Mathematical Modelling and Analysis of the Tumor Treatment Regimens with Pulsed Immunotherapy and ChemotherapyThe anticancer immune response: indispensable for therapeutic success?Irradiation of necrotic cancer cells, employed for pulsing dendritic cells (DCs), potentiates DC vaccine-induced antitumor immunity against high-grade glioma.Dendritic cell-based active specific immunotherapy for malignant glioma.Different effects of KCa and KATP agonists on brain tumor permeability between syngeneic and allogeneic rat models.Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy.Combination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer.
P2860
Q24641823-468C0731-082D-495F-98E8-4507ECFEF793Q27024830-C98ED534-5189-405D-9D91-0EDB41787AB8Q27348437-442DD29B-501F-4A9B-8080-D97FBAFB99D2Q27686800-ACB147DC-75B0-4FF8-B409-172B20804369Q30402590-88E291D5-9DA5-4782-96D3-36FD70FEACD6Q30493889-2DEFD270-5D60-4111-8830-41885CEF9EC1Q31013320-8D526D53-79F5-473F-81C4-2ECB1CF17D95Q33668084-7CE193A2-D925-460D-A260-5477C673C5E8Q33756244-758533F6-3795-4756-89AF-C5510013D027Q33828114-34C4B764-1FB0-4570-9AA0-27916A58D43BQ34052702-5EDEF87F-ED2A-4A18-8D7B-A65758049788Q34111882-14064756-8B18-4EEA-81D4-029D61ABCC39Q34189694-6C164431-EE90-438E-8EB1-EAB097F688E0Q34242939-CD7F745F-4806-4BB8-A54A-DB10CC646B55Q34243550-1C3D6D6E-1C62-43C6-843A-4C1E2182C66EQ34523918-F9D875E1-F7A6-4BB5-BF69-EFE4B57AD08EQ34722857-5C0BEFCA-C885-413A-ABF4-B78136B8907FQ34764143-20842598-DE96-419F-9395-C54BC7A0BBD0Q35136043-BBA5E1B9-16C4-47F2-8D94-934F24DFD3C0Q35285859-2CFE518A-B1AF-4617-9B4C-AA55E2F46441Q35527165-19B33999-D49D-48F1-8A18-9851D1E577EEQ35655447-214E91FA-76B2-4880-8DED-F4E06036AC4DQ35783111-8E0556BD-BD84-4A6C-877C-0FEEFF38B4F5Q35821404-80C9F40B-5FC9-4173-8D2E-59AD045D2231Q35992355-3790D692-6B2A-4A92-8035-8E667D6154F6Q36198607-059DEED1-6727-4991-B569-CE88A5A3EAC6Q36284489-23A8A4AE-EEFB-4D2F-B26E-6595162FBF2DQ36345439-AC8C7D69-683C-4DA5-9635-B98E8F656664Q36367428-12113609-4569-4DB4-817F-FB52703B1C52Q36445546-0A0066D7-E762-4346-ADAD-81795483DBF7Q36480998-92A49A94-1B8D-4616-B5F0-1F5FA3285A9AQ36632306-D428BAE3-639D-49BE-AA2A-0057B3385B75Q36653979-0948BCB6-FA69-455D-8A72-B4F1C64E101CQ36656344-D83F9226-66CB-4440-9278-42503127B27EQ36677608-2FEBDB03-56AE-4232-89D8-0CFCE96704C2Q36710917-7959D9AF-BEFA-4C3B-AB20-2AA83C08AD8CQ36764903-A8C48465-C77E-487A-9CD9-D32CE4CEED09Q37020323-109DE429-D006-4FBB-90D5-EE4868EAADACQ37154132-43B3830A-320C-47B9-9236-CA2B207AC306Q37299843-B2E2B573-F2C9-4D65-885A-C15CE4E38F3F
P2860
Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination.
@en
Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination.
@nl
type
label
Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination.
@en
Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination.
@nl
prefLabel
Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination.
@en
Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination.
@nl
P2093
P1476
Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination.
@en
P2093
Christopher J Wheeler
Gentao Liu
Keith L Black
P304
P356
10.1158/1078-0432.CCR-04-0497
P407
P577
2004-08-01T00:00:00Z